Skip to main content
    I

    Intensity Therapeutics, Inc. Common stock (INTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.07
    -0.01 (-0.32%)

    Market Cap: $10.17M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Intensity Therapeutics, Inc. Common stock (INTS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Intensity Therapeutics, Inc. Common stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$11.61M, operating cash flow was -$9.23M and free cash flow was -$9.23M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$3.54M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $11.97M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Research and development$6.79M$10.50M$4.79M$5.13M$5.86M$5.05M$4.44M
    Operating income-$11.97M-$16.59M-$8.32M-$7.55M-$8.01M-$6.22M-$5.68M
    Net income-$11.61M-$16.27M-$10.54M-$7.58M-$7.89M-$5.96M-$5.23M
    EBITDA-$11.79M-$16.58M-$8.16M-$7.37M-$8.01M-$6.22M-$5.68M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0-$26.00K$0$0$0$24.00K$0$0$0$282.22K
    Gross profit$0$0$0-$7.00K$0$0$0$12.00K$0$0$0$276.32K
    Operating income-$3.62M-$3.08M-$2.53M-$3.14M-$2.73M-$2.71M-$3.39M-$3.20M-$3.57M-$5.07M-$4.74M-$3.35M
    Net income-$3.54M-$3.01M-$2.43M-$3.05M-$2.67M-$2.54M-$3.35M-$3.18M-$3.51M-$4.97M-$4.60M-$3.17M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $31.00K by $11.89M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$14.10M$4.78M$17.30M$1.76M$5.22M$10.15M$9.01M
    Current assets$12.71M$3.36M$15.46M$1.45M$4.73M$9.48M$8.65M
    Cash and equivalents$11.92M$2.59M$8.56M$1.31M$4.54M$9.32M$3.83M
    Total liabilities$2.23M$1.86M$4.13M$6.86M$13.90M$11.71M$1.31M
    Short-term debt$31.00K$28.00K$20.00K$4.49M$2.20M$171.23K$117.19K
    Shareholder equity$11.88M$2.92M$13.16M-$15.10M-$8.68M-$1.56M$7.70M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$10.29M$11.52M$12.29M$14.10M$9.59M$4.44M$3.06M$4.78M$5.21M$8.67M$12.41M$17.30M
    Total liabilities$2.63M$2.31M$2.31M$2.23M$2.36M$2.26M$2.73M$1.86M$2.43M$3.33M$2.69M$4.13M
    Cash and equivalents$8.49M$9.53M$10.24M$11.92M$7.07M$2.22M$929.00K$2.59M$2.78M$3.24M$7.46M$8.56M
    Shareholder equity$7.65M$9.21M$9.98M$11.88M$7.22M$2.18M$334.00K$2.92M$2.78M$5.34M$9.72M$13.16M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$9.23M-$15.22M-$7.21M-$5.48M-$6.83M-$5.37M-$4.42M
    Capital expenditures$0$0$0$0$3$0$0
    Free cash flow-$9.23M-$15.22M-$7.21M-$5.48M-$6.83M-$5.37M-$4.42M
    Dividends paidN/AN/A$1.32MN/AN/AN/AN/A
    Share repurchases$1.82M$653.00K$0$0N/AN/AN/A
    Investing cash flow$0$6.35M-$6.02M$0N/A$4.56M$1.70M
    Financing cash flow$18.56M$2.90M$20.47M$2.25M$2.05M$6.29M$3.86M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.50M-$2.34M-$1.83M-$2.40M-$2.39M-$2.46M-$1.99M-$2.67M-$3.97M-$4.21M-$4.37M-$946.00K
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$0$0$3
    Free cash flowN/AN/A-$1.83M-$2.40M-$2.39M-$2.46M-$1.99M-$2.67M-$3.97M-$4.21M-$4.37M-$946.00K
    Last 12 quarters

    Frequently Asked Questions About INTS

    What is Intensity Therapeutics, Inc. Common stock's annual revenue?

    Intensity Therapeutics, Inc. Common stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Intensity Therapeutics, Inc. Common stock profitable?

    No. Intensity Therapeutics, Inc. Common stock reported net income of -$11.61M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does INTS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.23M minus capital expenditures of $0 produced free cash flow of -$9.23M.

    How much debt does Intensity Therapeutics, Inc. Common stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $31.00K and cash and equivalents of $11.92M.